Microtubule associated proteins as targets for anticancer drug development

Area of Science:

• Cell Biology
• Molecular Biology
• Cancer Research

Background:

• The dynamic equilibrium of tubulin-microtubule is crucial for cell survival and is a significant target in cancer drug development.
• Microtubules are essential for mitosis and cell division; antitubulin drugs exploit this by disrupting microtubule dynamics to eliminate cancer cells.
• Microtubule Associated Proteins (MAPs) modulate microtubule stability, and their inhibitors are under investigation for cancer therapy.

Purpose of the Study:

• To review Microtubule Associated Proteins (MAPs) and their role in cancer progression.
• To discuss the development and prospects of MAPs inhibitors as anticancer agents.
• To highlight the connection between post-translational modifications (like lysine-40 acetylation) and cancer treatment strategies involving HDAC inhibitors.

Main Methods:

• Literature review of existing research on MAPs, antitubulin drugs, and HDAC inhibitors.
• Analysis of the mechanisms by which MAPs and their inhibitors affect microtubule dynamics.
• Examination of the role of post-translational modifications, specifically lysine-40 acetylation, in gene expression and cancer.

Main Results:

• Antitubulin drugs and MAPs inhibitors disrupt microtubule dynamics, leading to cancer cell death.
• Histone deacetylase (HDAC) inhibitors demonstrate anticancer properties by inducing cell cycle arrest and apoptosis.
• Several tubulin-binding drugs and MAPs inhibitors are in clinical trials, indicating therapeutic potential.

Conclusions:

• MAPs represent a promising target for novel cancer therapies.
• Inhibitors of MAPs and HDACs offer potential strategies for cancer treatment, with several agents in clinical development.
• Understanding the interplay between microtubule dynamics, MAPs, and epigenetic modifications is vital for advancing cancer drug discovery.